Phase 2 study of second-line FOLFIRI-aflibercept in prospectively stratified, RAS wild type, anti-EGFR resistant, metastatic colorectal cancer patients: The DISTINCTIVE trial.

Eleonora Lai,Fotios Loupakis,Pina Ziranu,Giuseppe Aprile,Alberto Zaniboni,Clelia Madeddu,Sara Lonardi,S. Mosconi,Valeria Smiroldo,Giordano D. Beretta,Sabina Murgioni,Gerardo Rosati,M. Giulia Zampino,Fabio Gelsomino,Veronica Conca,Luigi Mascia,Luigi Cavanna,C. Morelli,Silvia Della Torre,Mario Scartozzi

Phase 2 study of second-line FOLFIRI-aflibercept in prospectively stratified, RAS wild type, anti-EGFR resistant, metastatic colorectal cancer patients: The DISTINCTIVE trial.

2021

e15503Background: Data on anti-angiogenic second line treatment in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) progressing after first-line anti-EGFR drug are lacking and ...

Keywords:

Internal medicine
Medicine
second line
Colorectal cancer
Oncology
Phases of clinical research
FOLFIRI
second line treatment
Aflibercept
Wild type

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations